Key Points: TPM® Oxymorphone Patch pre-IND, FDA face-to-face...

Key Points:

 TPM® Oxymorphone Patch pre-IND, FDA face-to-face meeting confirmed for December ‘18.

 Injectable candidates continue to progress – development candidates on track for 2018 Tox

 Multiple companies undertaking due diligence on Animal Health Business.

 Strong Vital ET sales on forecast for 2018

 Independent research coverage rates POH a ‘Buy’ with target 8-9 cents share price

 Mylan Arbitration Outcome: still to come

still to come..yes, we know